Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

Cambridge, USA-based biotech Repertoire Immune Medicines today announced a collaboration and license agreement with Genentech ...

Repertoire Immune Medicines has entered into a collaboration and license agreement with Genentech to discover and develop innovative T cell-targeted immune medicines.

Roche, and Genentech. In the U.S., Genentech markets the drug under the name HEMLIBRA (emicizumab-kxwh), with "kxwh" assigned per FDA guidance on naming biological products. HEMLIBRA can be ...

Genentech announced that new data were presented ... Results from 604 participants in a multicenter study of Roche’s (RHHBY) Elecsys pTau181 plasma test were presented, demonstrating its ...

Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder ...

https://www.tipranks.com/news/the-fly/roches-genentech-present-data-on-trontinemab-elecsys-plasma-test Genentech announced that new data were presented at the AD/PD ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data were presented at the AD/PD 2025 International Conf ...